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Abstract
Background: Trauma is one of the leading causes of death worldwide, with acute blood loss being the cause
of death for nearly one third of in-hospital trauma deaths. In response to trauma the clotting cascade begins
clotting to stop acute hemorrhaging with subsequent fibrinolysis to maintain proper hemostasis. Tranexamic
acid (TXA), an anti-fibrinolytic, has been used in elective surgeries to decrease blood loss. TXA does not
currently have widespread use in United States emergency departments or pre-hospital settings. Recombinant
Factor VIIa has been used in United States trauma centers but has not demonstrated an improvement in
mortality. No randomized control trials have proven to be effective in decreasing mortality from blood loss in
trauma patients. Will the administration of tranexamic acid have an effect on mortality due to hemorrhage in
trauma patients?
Method: An exhaustive search was conducted using Medline-OVID, CINAHL, EBMR Multifile, and Web of
Science using the keywords: trauma, wounds and injuries, and tranexamic acid. Relevant articles were
assessed for quality using GRADE. A search on the NIH clinical trials site reveals there are no trials currently
registered relating to the use of tranexamic acid (TXA) in trauma patients.
Results: Two studies met inclusion criteria and were included in this systematic review. A randomized,
double blind, placebo-controlled trial with 20 211 participants demonstrated a statistically significant
reduction in all-cause mortality with no increase in vascular occlusive events when TXA was administered. A
retrospective observational study with 896 participants demonstrated a statistically significant reduction in
mortality when TXA was administered, with the greatest benefit witnessed in those receiving a massive
transfusion. In addition, the cohort receiving TXA also demonstrated a decrease in coagulopathies. The
patients receiving TXA were also more severely injured.
Conclusion: TXA has been shown to reduce mortality from acute blood loss if given within three hours and
the greatest benefit is conferred if administration is within the first hour. There was no definitive evidence of
increased risk of blood clots or death from clotting events. In addition, the low cost of TXA makes the drug
affordable for urban and rural emergency departments as well as EMS. A strong recommendation can be made
for the use of TXA in trauma. More research is needed to determine the precise mechanism of action in
trauma.
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Abstract   
Background: Trauma is one of the leading causes of death worldwide, with acute blood 
loss being the cause of death for nearly one third of in-hospital trauma deaths.  In 
response to trauma the clotting cascade begins clotting to stop acute hemorrhaging with 
subsequent fibrinolysis to maintain proper hemostasis. Tranexamic acid (TXA), an anti-
fibrinolytic, has been used in elective surgeries to decrease blood loss. TXA does not 
currently have widespread use in United States emergency departments or pre-hospital 
settings. Recombinant Factor VIIa has been used in United States trauma centers but has 
not demonstrated an improvement in mortality.  No randomized control trials have 
proven to be effective in decreasing mortality from blood loss in trauma patients.  Will 
the administration of tranexamic acid have an effect on mortality due to hemorrhage in 
trauma patients? 
 
Method: An exhaustive search was conducted using Medline-OVID, CINAHL, EBMR 
Multifile, and Web of Science using the keywords: trauma, wounds and injuries, and 
tranexamic acid.  Relevant articles were assessed for quality using GRADE.  A search on 
the NIH clinical trials site reveals there are no trials currently registered relating to the 
use of tranexamic acid (TXA) in trauma patients.  
 
Results: Two studies met inclusion criteria and were included in this systematic review. 
A randomized, double blind, placebo-controlled trial with 20 211 participants 
demonstrated a statistically significant reduction in all-cause mortality with no increase in 
vascular occlusive events when TXA was administered.  A retrospective observational 
study with 896 participants demonstrated a statistically significant reduction in mortality 
when TXA was administered, with the greatest benefit witnessed in those receiving a 
massive transfusion.  In addition, the cohort receiving TXA also demonstrated a decrease 
in coagulopathies.  The patients receiving TXA were also more severely injured.  
 
Conclusion:  TXA has been shown to reduce mortality from acute blood loss if given 
within three hours and the greatest benefit is conferred if administration is within the first 
hour.  There was no definitive evidence of increased risk of blood clots or death from 
clotting events.  In addition, the low cost of TXA makes the drug affordable for urban 
and rural emergency departments as well as EMS.  A strong recommendation can be 
made for the use of TXA in trauma.  More research is needed to determine the precise 
mechanism of action in trauma.   
 
Keywords: Trauma, tranexamic acid, mortality, human 
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Tranexamic acid: A Cost Effective Medication to Decrease Death From Acute Blood 
Loss in Trauma Patients 
BACKGROUND 
Worldwide 5.8 million people die annually from trauma, with 44% of those 
deaths attributed to homicide and road traffic crashes.1  Of the deaths attributed to 
hemorrhage, 33% - 56% occur pre-hospital.2  Up to one third of trauma deaths occur in-
hospital due to acute hemorrhage.3  Following trauma, the clotting cascade activates to 
reduce bleeding and subsequently begins lysing the clots to maintain proper hemostasis. 
Studies have demonstrated that trauma is the primary cause of coagulopathy following 
trauma.4  Hyperfibrinolysis is a possible complication following severe trauma, leading to 
increased bleeding and higher mortality rates.4, 5  Tranexamic acid (TXA) is a synthetic 
derivative of the amino acid lysine that inhibits fibrinolysis.6  The exact mechanism of 
action in trauma patients is not well understood.7  There is evidence that TXA also 
reduces inflammatory response, further demonstrating the lack of understanding the 
mechanism of action in trauma.8, 9  Studies have also shown that systemic inflammation 
occurs following trauma, suggesting that the anti-inflammatory action may be as 
beneficial as the antifibrinolysis.10, 11  TXA is currently used in the United States for 
elective surgeries, post partum hemorrhage and heavy menstrual bleeding but is not 
widely used in emergency departments. Recombinant Factor VIIa is used in some U.S. 
emergency departments despite conflicting evidence supporting its efficacy in reducing 
mortality from trauma.12, 13  The cost of 1gm TXA in 10mL solution is $91.99 (CVS 
Pharmacy staff, April 2012, personal communication).  Morse et al12 examined rFVIIa in 
patients requiring massive transfusion with standard dosing of 4mg.  The cost of rFVIIa 
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2mg and 5mg is $3340 and $8350 respectively (wholesale cost, Novo Nordisk US staff, 
April 2012, personal communication).  A cost analysis of the CRASH-2 Trial has 
demonstrated TXA is cost effective in low, middle, and high income settings.14  TXA has 
been shown to reduce the number of units of packed red blood cells (PRBC) needed for 
transfusion following surgery.15  Studies of TXA have demonstrated a small number of 
adverse reactions but overall it has proven to be safe in multiple trials.16-19  Death from 
trauma is avoidable and one of the top causes of death worldwide.  An effective 
medication has the potential to save thousands of lives annually.  Will the administration 
of tranexamic acid have an effect on mortality due to hemorrhage in trauma patients? 
METHOD 
  An exhaustive search of available medical literature was conducted using 
Medline-OVID, CINAHL, EBMR Multifile, and Web of Science using the keywords: 
trauma, wounds and injuries, and tranexamic acid.  The search was then narrowed to 
include only English language articles.  The bibliographies of the articles were further 
searched for relevant sources.  Articles with primary data evaluating efficacy of TXA in 
trauma patients were included.  Relevant articles were assessed for quality using the 
Grading of Recommendations, Assessment, Development and Evaluation (GRADE).20  A 
search on the National Institute of Health (NIH) clinical trials site revealed no currently 
registered trials, at any phase, relating to the use of tranexamic acid in trauma patients.  
RESULTS 
  The initial result of the search yielded 131 articles for review.  After screening 
relevant articles for primary data and human studies, a total of 2 articles met inclusion 
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criteria.  These articles include one randomized controlled trial21 and one retrospective 
observational study22. 
CRASH-2 Trial  
  This randomized, double blind, placebo-controlled trial21 investigated the effect of 
TXA administration on mortality, vascular occlusive events, and volume of blood 
transfusion.  The placebo packaging was indistinguishable from the TXA.  The trial 
enrolled 20 211 adult trauma patients in 274 hospitals in 40 countries, with, or at risk of, 
significant bleeding and assigned participants to the TXA group or the placebo group. 
The primary outcome was mortality within 4 weeks of injury, and cause of death 
described as: bleeding, vascular occlusive, multiorgan failure, head injury or other.  
Secondary outcomes included myocardial infarction, stroke, pulmonary embolism and 
deep vein thrombosis, surgical intervention, required blood transfusion and number of 
units of PRBC.  In addition data for the use of recombinant Factor VIIa and for GI bleed 
were also collected21.  
  Eligibility criteria consisted of patients with significant hemorrhage and SBP < 
90mmHg or heart rate >110 beats per minute, or both, or deemed to be at risk for 
significant hemorrhage; and within 8 hours of injury.  Patients were randomly assigned 
when the attending provider was uncertain if TXA was required.  If the provider was 
certain TXA was indicated or was contraindicated, the patients were assigned to the 
respective cohort without randomization.  The randomization service employed an 
algorithm to maintain prognostic balance, it considered sex, age, time since injury, type 
of injury, Glasgow Coma Scale (GCS), Systolic Blood Pressure (SBP), respiratory rate, 
central capillary refill time, country, and whether or not TXA was available at that 
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hospital.  Patients receiving TXA were given a loading dose of 1gm IV over 10 minutes, 
followed by an infusion of 1gm over 8 hours21.  
  Treatment groups were balanced to all baseline patient characteristics.  There 
were 10 060 patients allocated to the TXA cohort and 10 067 to placebo cohort with 
99.1% of patients completing the loading dose and 94.2% completing the maintenance 
dose.  Of the 3076 patients who died, 35.3% died on the day of randomization.  And, of 
the 1063 deaths attributed to bleeding, 59.9% occurred on the day of randomization.21  
  Tranexamic Acid administration significantly reduced all-cause mortality (RR 
0.91, 95% CI 0.85-0.97, p=0.0035, NNT = 67) and death due to bleeding was also 
significantly reduced overall (RR 0.85, 95% CI 0.76-0.96, p=0.0077) and on the day of 
randomization (RR 0.80, 95% CI 0.68-0.93, p=0.0036).  Deaths from vascular occlusion, 
although not significant, were fewer in the TXA cohort.  There was a statistically 
significant reduction in event rates of myocardial infarction (MI) with TXA 
administration, while there was not a statistically significant difference in rates of stroke, 
deep venous thrombosis (DVT), and pulmonary thromboembolism (PTE).  Only 50% of 
patients received a blood transfusion in this study, with no difference between the TXA 
and the no-TXA groups.  The TXA group received a mean of 6.06 units of PRBC while 
the no-TXA group received a mean of 6.29 units.  Surgical intervention was performed in 
48% of patients in each group.  13 patients in the TXA group received recombinant 
Factor VIIa and only 4 patients in the no-TXA group received it.21. 
  The authors found that limitations to this study included the difficulty of 
diagnosing traumatic hemorrhage and that some patients were not bleeding at the time of 
randomization may have been included in the study, possibly reducing the power of the 
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trial.  They also discussed the difficulty of diagnosing vascular occlusive events, which 
required clear clinical evidence, thus, there was a risk of underreporting.  The authors 
recommended that tranexamic acid be considered for inclusion on the WHO List of 
Essential Medicines, and considered for use in bleeding trauma patients.21 
MATTERs Study 
  In this retrospective observational study22 the authors compared the 
administration of TXA to no-TXA in patients suffering trauma and requiring at least one 
unit of PRBC.  They also examined patients requiring a massive transfusion (designated 
as TXAMT and no-TXAMT), greater than 10 units of PRBC.  This study included only 
patients treated at a Role 3 Echelon surgical hospital in Afghanistan.  The authors 
reviewed 896 consecutive admissions from trauma due to combat injury for which the 
patients had received at least one unit of PRBC transfusion.  Of those admitted, 293 
received TXA.  The patients included in the study consisted of US and UK military 
members as well as Afghan nationals.  The data were compiled from both the UK and US 
trauma registries.  Standard dosing for the military is a single 1gm TXA IV bolus initially 
and repeated as deemed necessary by the attending clinician.  The authors further 
investigated patients receiving a massive transfusion and split them into two groups: 
those receiving TXA, 125 patients, and those not receiving TXA, 196 patients.22  
  The primary endpoint was mortality, which was investigated at 24 hours, 48 
hours, and 30 days.  Secondary endpoints included transfusion requirements, coagulation 
parameters (Prothrombin Time (PT), activated Partial Thromboplastin Time (aPTT)), and 
thrombotic events (DVT, PTE).  Hypocoagulopathy was defined as PT > 18 seconds and 
aPTT > 55 seconds based on data from a previous study.23  Data collected included 
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admission physiology, treatment timelines, and a 24-hour transfusion requirement 
(PRBCs, Fresh Frozen Plasma (FFP), platelets, and cryoprecipitate).  The Glasgow Coma 
Scale score, systolic blood pressure and respiratory rate at admission were used to 
generate a Revised Trauma Score (RTS), which is inversely related to trauma mortality.24  
The authors calculated the Injury Severity Score (ISS)25 from time of admission and 
utilized the Abbreviated Injury Scale to report the anatomical injury pattern for 4 body 
regions (head, chest, abdomen, and extremity).24  The guidelines established for inclusion 
in the study included hypotension: Systolic Blood Pressure < 90mm Hg or lower, a GCS 
< 8, and severe injury as an Abbreviated Injury Scale score > 3. 22 
  The data analysis demonstrated that the mean dose of TXA administered within 
one hour of injury was 2.3gm.  Overall, those receiving TXA had a higher Injury Severity 
Scale (ISS) score, a higher percentage of patients with severe extremity injury, a lower 
Revised Trauma Score, and a greater percentage of patients presenting with a depressed 
GCS score and hypotension.  In patients receiving massive transfusion, the TXAMT group 
had a greater percentage of patients with severe extremity injury and a great percentage 
of patients with a depressed GCS score compared to the no-TXAMT group.  The TXA 
cohort required a greater number of PRBC units, while the massive transfusion subgroup, 
transfusion requirements were similar in the TXAMT and no-TXAMT groups.  In addition, 
the ratio of PRBC:FFP was equivalent in both the overall cohorts and massive transfusion 
subgroups.  However, in the massive transfusion subgroups, the TXAMT group received 
more cryoprecipitate than the no-TXAMT group.  In both the overall cohorts and MT 
subgroups, rates of DVT and PTE were higher in the TXA group.  PTE was not indicated 
as the cause of death in any patient in the study.  When evaluating hypocoagulopathy at 
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time of admission and in the ICU, TXA significantly improved coagulation markers. 
Reduction in the mortality rate of patients receiving TXA was significant at 48 hours and 
30 days in both the entire study and the MT subgroup.22  
  The MATTERs Study authors concluded that TXA is effective in decreasing all-
cause mortality (RR 0.73, p=0.03, NNT = 15) and hypocoagulopathy in trauma patients 
receiving at least one unit of PRBC, and identified the greatest efficacy in reducing 
mortality in patients receiving a massive transfusion (RR 0.51, p=0.004, NNT = 7).  The 
authors speculated that the higher rates of DVT and PTE in those receiving TXA may be 
due to the higher injury burden or due to the survivorship phenomenon as the TXA 
cohort had a relative risk reduction of mortality of 27% overall and 49% in the MT 
cohort.  The authors recommended that early administration of TXA following severe 
wartime vascular disruption with hemorrhage should be implemented into clinical 
practice.22 
DISCUSSION 
Tranexamic acid is a cost effective, life saving drug that is not currently widely 
used in United States emergency departments.  Following the publication of the CHASE-
2 Trial, Massachusetts General was the only emergency department utilizing the drug for 
trauma patients26, and more may be utilizing the medication at this time.  In 2011, TXA 
was added to the WHO List of Essential Medicines based on its efficacy, safety, cost and 
the  high number of deaths related to trauma worldwide.  While some emergency 
departments have medications that are much more expensive at their disposal for trauma 
patients, TXA is a medication that can significantly improve mortality at a fraction of the 
cost of drugs like recombinant Factor VIIa.  Due to the demonstrated importance of early 
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administration, TXA should be considered in pre-hospital settings as well.2, 27-29  
Research has shown that transportation directly to major trauma centers has reduced 
overall mortality but has increased the time from injury to presentation at a hospital, 
further supporting the use of TXA in pre-hospital settings.30  The US military has issued 
proposed guidelines for its use including an intramuscular autoinjector for use in the 
battlefield.31, 32  Austrlia has proposed guidelines for pre-hospital use as well.33  
Tranexamic acid has been proven to be safe with no increase in blood clots or death 
related to the administration of the drug.  It also has demonstrated improvement in 
coagulopathies from the time of initial marker compared to the next laboratory draw in 
the ICU.  In addition, further subgroup analysis of patients with traumatic brain injury by 
CRASH-2 collaborators, found they could not exclude moderate benefits nor moderate 
harmful effects, however data suggested outcomes might improve following TBI when 
TXA was administered.34  Recombinant Factor VIIa has proven to improve mortality at 
24 hours, but has failed to demonstrate a mortality improvement at 30 days.12, 13, 35  This 
data suggests that Recombinant Factor VIIa, a drug that is more expensive than TXA, 
also increases cost of hospital admission due to an emergent procedure and ICU stay with 
no benefit to mortality rates.  An August 2011 recommendation to the Committee on 
Tactical Combat Casualty Care (TCCC) has recommended a TXA 1gm IV bolus over 10 
minutes followed by another TXA 1 gm infusion over 8 hours. The TCCC also noted the 
cost of administering TXA is lower than that of administering one unit of PRBC in a 
combat setting.  The CRASH-2 collaborators found TXA is most effective when 
administered within the first hour post injury, and the greatest likelihood of benefit 
requires administration within the first 3 hours.29  TXA is the only drug, at this time that 
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has demonstrated an all-cause and bleeding death mortality benefit in a prospective, 
randomized, controlled-trial.  
While the studies21, 22 demonstrated that TXA is effective, they both have 
limitations.  In the CRASH-2 trial, receiving providers made the decision between a 
strong indication for TXA, a contraindication for TXA or a lack of certainty.  When the 
provider was unsure, that patient was then randomized, and in response to ethical 
constructs when the provider deemed there to be a strong indication or contraindication 
for TXA, patients were placed in the TXA or no-TXA cohorts, respectively.  The TXA 
group required more units of blood than the no-TXA cohort suggesting, as the MATTERs 
trial did, that efficacy increases with severity of hemorrhage or the data could be due to 
the survivorship bias in which patients who survive longer require more units of blood 
products.  Further analysis from the full data set36 of the CRASH-2 Trial data 
demonstrated inconsistencies with the MATTERs Study in the massive transfusion 
subgroup analysis, with 40% mortality and 14.4% mortality respectively, however, when 
compared to no-TXA, the RR was 0.53 in the CRASH-2 Trial and 0.51 in the MATTERs 
Study.  The inconsistency in the TXA groups may be due to a limitation in the CRASH-2 
Trial which allowed the receiving physician to determine a definite indication for TXA 
and place the patient in the TXA group.  Another possible cause of the inconsistency may 
be due to the location of the study in which no United States facilities were involved and 
75% of the participants were from India, Colombia, Egypt, Nigeria, Georgia and 
Ecuador,32 which may not have had the capabilities to manage patients with severe 
hemorrhage.   
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The MATTERs Study is limited due to being an observational study.  Conversely, 
this retrospective study was able to provide more details about the patient’s severity that 
was not available in the CRASH-2 trial.  Injury severity score, revised trauma score and 
abbreviated injury scale were documented providing a better description of the acuity of 
the patients. Due to the retrospective nature of the study, there were no clinical practice 
guideline parameters for the administration of TXA.  The authors suspect there is little 
variation as all patients were treated at the same facility.22  The secondary outcomes 
examined also had potential for errors as there were no predefined criteria prior to the 
study. Follow up with the UK and US service members was complete.  However, follow 
up with Afghan nationals was not completed following their discharge from the medical 
facility.  Afghan national patients were discharged only when they were stable making it 
unlikely there was a significant number of unreported deaths.  No deaths from PTE were 
demonstrated in either cohort in the MATTERs Study.  
CONCLUSION 
  Tranexamic Acid has been demonstrated to be a cost effective method of reducing 
all cause mortality and mortality due to hemorrhage in trauma patients when administered 
within 3 hours of injury.  More specifically, the evidence supports its use with patients 
requiring a transfusion.  The benefits of this treatment outweigh the risks in the setting of 
traumatic hemorrhage.  The overall combined quality of the studies reviewed is moderate 
based on the GRADE criteria.  A strong recommendation for the use of tranexamic acid 
in trauma patients with acute blood loss requiring at least one unit of packed red blood 
cells can be given.  Tranexamic Acid should also be considered for use in pre-hospital 
settings due to the demonstrated increase in efficacy with early administration.  Research 
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to better understand the mechanism of action of tranexamic acid in acute blood loss is 
needed.  Further randomized controlled studies designed to evaluate the effect on 
mortality may be unlikely. 
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TABLES 
Table 1: GRADE evidence profile: Tranexamic acid for trauma patients with acute blood loss 
Abbreviations: GRADE: Grading of Recommendations, Assessments, Development and Evaluation. 
sCause of death is unknown in the MATTERs trial due to being a retrospective study.   
bData obtained from the CRASH-2 Trial data set.36   
c No deaths were observed from PE in the MATTERs Study, due to the retrospective nature, guidelines for diagnosing vascular occlusive events was unknown by the authors.  Mortality from all vascular occlusion in the CHASE-2 Trial was 33 (0.3%) and 48 (0.5%) in the 
TXA and no-TXA cohorts respectively. 
Quality Assessment Summary of Findings 
Importance 
 Downgrade Criteria Upgrade Criteria  Number of Patients Effect 
Quality No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Large 
effective 
Magnitude 
Confounding 
Factors 
reducing 
effect 
Dose-
response 
gradient 
Study TXA Placebo or no-TXA 
Relative 
Risk NNT/NNH 
Mortality (All-Cause) 
2 
 
1 RCT 
1 Observational 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely - -
 - 
CRASH-2 1463/10,060 1613/10,067 0.91 NNT 67 Moderate Critical 
MATTERs 51/293 144/603 0.73 NNT 16 
Mortality from blood lossa in patients receiving at least one unit of PRBC and receiving intervention within one hour of injury 
2 1 RCT 1 Observational 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely - - - 
CRASH-2 198/3747 286/3704 0.69 NNT 42 Moderate Critical 
MATTERs 51/293 144/603 0.73 NNT 16 
Mortality after receiving Massive Transfusion ( > 10 units PRBC) and receiving intervention within one hour of injury 
2 1 RCT 1 Observational 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely - - - 
CRASH-2b 90/225 3/4 0.53 NNT 3 Moderate Critical 
MATTERs 18/125 55/196 0.51 NNT 7 
Pulmonary Embolism eventsc 
2 1 RCT 1 Observational 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely - - - 
CRASH-2 72/10,060 71/10,067 1.01 NNH 10,000 Moderate Critical 
MATTERs 8/293 2/603 9 NNH 42 
Deep Vein Thrombosis eventsc 
2 1 RCT 1 Observational 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias 
likely - - - 
CRASH-2 40/10,060 41/10,067 0.98 NNH 10,416 Moderate Important 
MATTERs 7/293 1/603 12 NNH 46 
